ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours

[1]  S. Swaminathan.  Protein quality control: knowing when to fold , 2005, Nature Cell Biology.

[2]  T. Mukohara,et al.  Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). , 2003, Lung cancer.

[3]  P. Clarke,et al.  Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK , 2003, Nature Cell Biology.

[4]  M. Tsao,et al.  Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  J. Arbiser,et al.  Mitogen-actived protein kinase activation is an early event in melanoma progression. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  J. Brognard,et al.  Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants , 2002, Cell Death and Differentiation.

[7]  R. Lai,et al.  Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. , 2002, Journal of clinical pathology.

[8]  A. Adjei,et al.  Novel targets for lung cancer therapy: part I. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Murphy,et al.  Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  M. Volm,et al.  Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  J. Baselga,et al.  Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. , 2001, Cancer research.

[12]  I. Ellis,et al.  Phosphorylation of ERK1/2 mitogen‐activated protein kinase is associated with poor response to anti‐hormonal therapy and decreased patient survival in clinical breast cancer , 2001, International journal of cancer.

[13]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[14]  J. Ting,et al.  MEK Inhibition Enhances Paclitaxel-induced Tumor Apoptosis* , 2000, The Journal of Biological Chemistry.

[15]  S. Eppenberger-Castori,et al.  Potential prognostic value of mitogen‐activated protein kinase activity for disease‐free survival of primary breast cancer patients , 2000, International journal of cancer.

[16]  T. Mohr,et al.  Evidence for a role of FGF‐2 and FGF receptors in the proliferation of non‐small cell lung cancer cells , 1999, International journal of cancer.

[17]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[18]  G. Fontanini,et al.  The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. , 1999, Human pathology.

[19]  Takashi Tsuruo,et al.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.

[20]  H. Frierson,et al.  Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.

[21]  S. Vandenberg,et al.  In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. , 1998, The American journal of pathology.

[22]  J. Wityak,et al.  MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. , 1998, Bioorganic & medicinal chemistry letters.

[23]  M. Wigler,et al.  Signaling pathways in Ras-mediated tumorigenicity and metastasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  N. Hayashi,et al.  Activation of mitogen‐activated protein kinases/extracellular signal‐regulated kinases in human hepatocellular carcinoma , 1998, Hepatology.

[25]  G. Nuovo,et al.  Hyperexpression of mitogen-activated protein kinase in human breast cancer. , 1997, The Journal of clinical investigation.

[26]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[27]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[28]  R. Figlin,et al.  Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. , 1995, Oncogene.

[29]  O Yoshida,et al.  Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. , 1995, Cancer research.

[30]  J. Fraumeni,et al.  Recent cancer trends in the United States. , 1995, Journal of the National Cancer Institute.

[31]  A. Bridges,et al.  A synthetic inhibitor of the mitogen-activated protein kinase cascade. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Minna,et al.  Molecular pathogenesis of lung cancer. , 1994, Annual review of physiology.

[33]  A. Adjei,et al.  Novel targets for lung cancer therapy: part II. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Baselga,et al.  Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Widmann,et al.  Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. , 1999, Physiological reviews.